Compare VET & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VET | DVAX |
|---|---|---|
| Founded | 1994 | 1996 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | N/A | 2004 |
| Metric | VET | DVAX |
|---|---|---|
| Price | $8.26 | $15.41 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $26.50 |
| AVG Volume (30 Days) | 1.5M | ★ 5.0M |
| Earning Date | 11-05-2025 | 02-19-2026 |
| Dividend Yield | ★ 4.53% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,445,514,003.00 | $330,514,000.00 |
| Revenue This Year | $11.40 | $24.63 |
| Revenue Next Year | N/A | $15.85 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 30.48 | 26.73 |
| 52 Week Low | $5.14 | $9.20 |
| 52 Week High | $10.49 | $15.49 |
| Indicator | VET | DVAX |
|---|---|---|
| Relative Strength Index (RSI) | 48.46 | 88.47 |
| Support Level | $7.76 | $10.78 |
| Resistance Level | $8.64 | $15.45 |
| Average True Range (ATR) | 0.25 | 0.10 |
| MACD | -0.01 | 0.15 |
| Stochastic Oscillator | 57.06 | 98.41 |
Vermilion Energy Inc is an international oil and gas-producing company. The company engages in full-cycle exploration and production programs that focus on the acquisition, exploration, development, and optimization of producing properties in North America, Europe, and Australia. The majority of Vermilion's revenue is derived from the production and sale of petroleum and natural gas. In each market, the company relies on a host of drilling and well-completion techniques to keep production at attractive levels. Geographically, the company derives majority of its revenue from Canada.
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.